Isatin |
Catalog No.GC12962
One-Click Copy Product Info
|
endogenous monoamine oxidase inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 91-56-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
IC50: 15 μM
Isatin is a monoamine oxidase inhibitor.
Monoamine oxidase inhibitors have been used as therapies for the treatment of depression, particularly in treating atypical depression. Monoamine oxidase inhibitors are also used in the treatment of Parkinson's disease and other disorders.
In vitro: Previous study found that isatin treatment at 1-400 μM for 24h could induce a significant dose-dependent increase in MTT metabolism by SH-SY5Y cells, which was not due to the increase in cell division. In addition, isatin at the higher concentrations was able to trigger cell death, though MTT metabolism was still increased, indicating that the surviving cells were hypermetabolic. With a longer treatment, isatin was found to cause cell death in a dose-dependent manner, and the predominant mode of cell death was apoptosis at lower concentrations, while at the highest concentration increasing numbers of necrotic cells were also observed [1].
In vivo: Animal study showed that the motor activity of Japanese encephalitis virus (JEV)-induced rats receiving isatin was improved significantly when compared with that of untreated JEV-infected rats. In addition, isatin was able to prevent the decrease in striatal DA levels in JEV-rats and the increased turnover of dopamine (DA) (DOPAC/DA) induced by JEV was significantly inhibited by isatin. Such results indicated that the exogenously administered isatin was able to improve JEV-induced parkinsonism via increasing the striatum DA concentrations [2].
Clinical trial: Up to now, isatin is still in the preclinical development stage.
References:
[1] Igosheva N,Lorz C,O'Conner E,Glover V,Mehmet H. Isatin, an endogenous monoamine oxidase inhibitor, triggers a dose- and time-dependent switch from apoptosis to necrosis in human neuroblastoma cells. Neurochem Int.2005 Aug;47(3):216-24.
[2] Hamaue N,Minami M,Terado M,Hirafuji M,Endo T,Machida M,Hiroshige T,Ogata A,Tashiro K,Saito H,Parvez SH. Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus. Neurotoxicology.2004 Jan;25(1-2):205-13.
| Cas No. | 91-56-5 | SDF | |
| Chemical Name | indoline-2,3-dione | ||
| Canonical SMILES | O=C(C1=O)C2=C(N1)C=CC=C2 | ||
| Formula | C8H5NO2 | M.Wt | 147.13 |
| Solubility | DMSO : 29mg/mL | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 6.7967 mL | 33.9836 mL | 67.9671 mL |
| 5 mM | 1.3593 mL | 6.7967 mL | 13.5934 mL |
| 10 mM | 679.7 μL | 3.3984 mL | 6.7967 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 12 reference(s) in Google Scholar.)